Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024
24 Luglio 2024 - 6:00PM
UK Regulatory
Oxurion Announces Results on the Extraordinary General Meeting
(EGM) of 24 July 2024
Oxurion Announces Results on the
Extraordinary General Meeting (EGM) of 24 July 2024
Leuven, BELGIUM – 24 July, 2024 – 06.00
PM CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company headquartered in Leuven, held an
Extraordinary General Meeting on July 24, 2024. The shareholders
approved all items on the agenda of the Extraordinary General
Meeting.
All documents pertaining to the Extraordinary
General Meeting held on July 24, 2024, can be consulted on
Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in
developing next-generation standard of care ophthalmic therapies
for the treatment of retinal disease. Oxurion is based in Leuven,
Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
Oxurion NV
Pascal Ghoson
Chief Executive Officer
pascal.ghoson@oxurion.com
|
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Feb 2024 a Feb 2025
